60 Degrees Pharmaceuticals (NASDAQ:SXTP) Receives “Neutral” Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a research report released on Friday morning,Benzinga reports.

60 Degrees Pharmaceuticals Stock Down 5.6 %

NASDAQ:SXTP traded down $0.05 during trading hours on Friday, reaching $0.90. 49,447 shares of the company’s stock were exchanged, compared to its average volume of 246,264. The company has a market capitalization of $1.67 million, a P/E ratio of 9.78 and a beta of 4.78. 60 Degrees Pharmaceuticals has a 12 month low of $0.70 and a 12 month high of $18.36. The business’s 50-day simple moving average is $1.09 and its two-hundred day simple moving average is $0.72.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($4.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.79) by ($1.44). The firm had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.11 million. As a group, sell-side analysts anticipate that 60 Degrees Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.